SEC Form 3 · accession 0001209191-15-032497
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William T. Andrews
Officer — See Remarks
Period of report
Mar 29, 2015
Accepted (ET)
Apr 3, 2015 · 7:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 4,660 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $13.39 | holding | — | — | — | — | May 1, 2022 | Common Stock | 50,000 | — | D |
| Stock Option (right to buy)F2 | $39.02 | holding | — | — | — | — | Apr 1, 2023 | Common Stock | 20,000 | — | D |
| Stock Option (right to buy)F3 | $47.11 | holding | — | — | — | — | Apr 1, 2024 | Common Stock | 17,000 | — | D |
Explanation of responses
- F1The shares of common stock underlying this option vest and become exercisable in equal monthly installments over 48 months from date of grant until May 1, 2016
- F2The shares of common stock underlying this option vest and become exercisable in equal monthly installments over 48 months from date of grant until April 1, 2017.
- F325% of the shares of common stock underlying this stock option award vested on April 1, 2015. The remaining 75% of the shares of common stock underlying this stock option award will vest in equal monthly installments through April 1, 2018.
Remarks
Senior Vice President, Business Development